Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiomyopathy, familial dilated.

Matthew R G Taylor1, Elisa Carniel, Luisa Mestroni

  • 1University of Colorado Cardiovascular Institute and Adult Medical Genetics Program, Department of Internal Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA. Matthew.Taylor@UCHSC.edu

Orphanet Journal of Rare Diseases
|July 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling the Hidden Rules: Enhancing NMD Prediction for Protein-Truncating Variants.

bioRxiv : the preprint server for biology·2026
Same author

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Circulation. Genomic and precision medicine·2026
Same author

The role of cardiac myosin activators in dilated cardiomyopathy pharmacotherapy.

Expert opinion on pharmacotherapy·2026
Same author

Sex and Age Specific Genetic Risk Across the Dilated and Arrhythmogenic Cardiomyopathy Spectrum: Insights From the SHaRe Registry.

Journal of the American College of Cardiology·2026
Same author

External validation of the DSP-risk score for prediction of clinically significant ventricular arrhythmias in primary prevention patients with desmoplakin cardiomyopathy-associated genetic variants.

Heart rhythm·2026
Same author

RBM20 Truncating Variants and Human Cardiomyopathy.

JAMA cardiology·2026

Familial dilated cardiomyopathy (FDC) is an inherited heart muscle disease often caused by genetic mutations. Early identification through family screening and genetic testing enables timely interventions to manage heart failure and improve outcomes.

Area of Science:

  • Cardiology
  • Genetics
  • Internal Medicine

Background:

  • Dilated cardiomyopathy (DCM) is a significant heart muscle disease marked by enlarged ventricles and reduced pumping function.
  • Familial DCM (FDC), accounting for 20-48% of DCM cases, stems from genetic mutations affecting cardiac myocyte proteins.
  • DCM presents risks of heart failure, arrhythmias, and premature death, with a prevalence of 1 in 2500.

Purpose of the Study:

  • To highlight the importance of family history analysis and genetic testing in identifying FDC.
  • To emphasize the benefits of early diagnosis for timely intervention and disease management.
  • To outline current management strategies for FDC, focusing on heart failure and arrhythmia control.

Main Methods:

  • Utilizing family history analysis and pedigree evaluation to identify at-risk families.

Related Experiment Videos

  • Employing clinical genetic testing for known FDC-associated genes.
  • Applying standard criteria for FDC family evaluation and screening.

    • Main Results:

    • Early or presymptomatic identification of FDC patients is achievable through screening.
    • Genetic counseling aids in identifying at-risk asymptomatic family members for regular monitoring.
    • Screening facilitates earlier lifestyle modifications and pharmacological therapy initiation.

    Conclusions:

    • Family screening and genetic testing are crucial for early FDC detection and management.
    • Proactive management, including lifestyle changes and pharmacotherapy, can mitigate disease progression.
    • Advanced therapies and heart transplantation remain options for severe FDC cases.